---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-032142"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-08-11T12:30:33+00:00"
generated_at: "2026-08-11T12:35:27.103193+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech refocuses on PDS0301 in mCRC; discontinues PDS0101 Phase 3 trial

## Summary
- PDS0301 showed 71% ORR at 6 months and 80% 24-month survival in MSS/pMMR mCRC with liver metastases.
- Company discontinues PDS0101 Phase 3 VERSATILE-003 trial and will pursue strategic partnerships for PDS0101.
- PDS0301 has been studied in >380 patients with encouraging safety; Phase 2b trial designed with FDA feedback.
- PDS0301 also evaluated in prostate, Kaposi sarcoma, HPV16+ cancers via NCI-sponsored trials.
- Q2 2026 financial results scheduled for announcement on August 13, 2026.

## SEC filing metadata
- accession: 0001140361-26-032142
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-08-11T12:30:33+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126032142/0001140361-26-032142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126032142/ef20079931_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-032142
- JSON: https://secwatch.observer/filing/0001140361-26-032142.json
- Plain text: https://secwatch.observer/filing/0001140361-26-032142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.